Home Infusion Therapy Market (By Product: Infusion Pumps, Intravenous Sets, IV Cannulas, Needleless Connectors; By Application: Anti-infective, Endocrinology, Hydration Therapy, Chemotherapy, Enteral Nutrition, Parenteral Nutrition, Specialty Pharmaceuticals, Others; By Route of Administration: Intramuscular, Subcutaneously, Epidural; By End User: Patients, Nurse, Hospitals, Others) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2022-2030
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Home Infusion Therapy Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Home Infusion Therapy Market, by Product, 2022-2030
8.1.1. Infusion Pumps
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Intravenous Sets
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. IV Cannulas
8.1.3.1. Market Revenue and Forecast (2017-2030)
8.1.4. Needleless Connectors
8.1.4.1. Market Revenue and Forecast (2017-2030)
9.1. Home Infusion Therapy Market, by Application e, 2022-2030
9.1.1. Anti-infective
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Endocrinology
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Hydration Therapy
9.1.3.1. Market Revenue and Forecast (2017-2030)
9.1.4. Chemotherapy
9.1.4.1. Market Revenue and Forecast (2017-2030)
9.1.5. Enteral Nutrition
9.1.5.1. Market Revenue and Forecast (2017-2030)
9.1.6. Parenteral Nutrition
9.1.6.1. Market Revenue and Forecast (2017-2030)
9.1.7. Specialty Pharmaceuticals
9.1.7.1. Market Revenue and Forecast (2017-2030)
9.1.8. Others
9.1.8.1. Market Revenue and Forecast (2017-2030)
10.1. Home Infusion Therapy Market, by Route of Administration, 2022-2030
10.1.1. Intramuscular
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Subcutaneously
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. Epidural
10.1.3.1. Market Revenue and Forecast (2017-2030)
11.1. Home Infusion Therapy Market, by Route of Administration, 2022-2030
11.1.1. Patients
11.1.1.1. Market Revenue and Forecast (2017-2030)
11.1.2. Nurse
11.1.2.1. Market Revenue and Forecast (2017-2030)
11.1.3. Hospitals
11.1.3.1. Market Revenue and Forecast (2017-2030)
11.1.4. Others
11.1.4.1. Market Revenue and Forecast (2017-2030)
12.1. North America
12.1.1. Market Revenue and Forecast, by Product (2017-2030)
12.1.2. Market Revenue and Forecast, by Application (2017-2030)
12.1.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.1.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Product (2017-2030)
12.1.5.2. Market Revenue and Forecast, by Application (2017-2030)
12.1.5.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.1.5.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Product (2017-2030)
12.1.6.2. Market Revenue and Forecast, by Application (2017-2030)
12.1.6.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.1.6.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Product (2017-2030)
12.2.2. Market Revenue and Forecast, by Application (2017-2030)
12.2.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.2.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Product (2017-2030)
12.2.5.2. Market Revenue and Forecast, by Application (2017-2030)
12.2.5.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.2.5.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Product (2017-2030)
12.2.6.2. Market Revenue and Forecast, by Application (2017-2030)
12.2.6.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.2.6.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Product (2017-2030)
12.2.7.2. Market Revenue and Forecast, by Application (2017-2030)
12.2.7.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.2.7.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Product (2017-2030)
12.2.8.2. Market Revenue and Forecast, by Application (2017-2030)
12.2.8.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.2.8.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Product (2017-2030)
12.3.2. Market Revenue and Forecast, by Application (2017-2030)
12.3.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.3.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Product (2017-2030)
12.3.5.2. Market Revenue and Forecast, by Application (2017-2030)
12.3.5.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.3.5.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Product (2017-2030)
12.3.6.2. Market Revenue and Forecast, by Application (2017-2030)
12.3.6.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.3.6.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Product (2017-2030)
12.3.7.2. Market Revenue and Forecast, by Application (2017-2030)
12.3.7.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.3.7.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Product (2017-2030)
12.3.8.2. Market Revenue and Forecast, by Application (2017-2030)
12.3.8.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.3.8.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Product (2017-2030)
12.4.2. Market Revenue and Forecast, by Application (2017-2030)
12.4.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.4.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Product (2017-2030)
12.4.5.2. Market Revenue and Forecast, by Application (2017-2030)
12.4.5.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.4.5.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Product (2017-2030)
12.4.6.2. Market Revenue and Forecast, by Application (2017-2030)
12.4.6.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.4.6.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Product (2017-2030)
12.4.7.2. Market Revenue and Forecast, by Application (2017-2030)
12.4.7.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.4.7.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Product (2017-2030)
12.4.8.2. Market Revenue and Forecast, by Application (2017-2030)
12.4.8.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.4.8.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Product (2017-2030)
12.5.2. Market Revenue and Forecast, by Application (2017-2030)
12.5.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.5.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Product (2017-2030)
12.5.5.2. Market Revenue and Forecast, by Application (2017-2030)
12.5.5.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.5.5.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Product (2017-2030)
12.5.6.2. Market Revenue and Forecast, by Application (2017-2030)
12.5.6.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.5.6.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.1. CVS/Coram
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Option Care Health
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. BriovaRx/Diplomat (UnitedHealth Optum)
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. PharMerica
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Fresenius Kabi
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. ICU Medical, Inc.
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. B. Braun Melsungen AG
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Baxter
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. BD
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Caesarea Medical Electronics
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample